662 related articles for article (PubMed ID: 17473568)
1. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
4. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
5. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.
Cracowski JL; Carpentier PH; Imbert B; Cachot S; Stanke-Labesque F; Bessard J; Bessard G
Arthritis Rheum; 2002 May; 46(5):1319-23. PubMed ID: 12115239
[TBL] [Abstract][Full Text] [Related]
6. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
Stoyneva Z
Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
[TBL] [Abstract][Full Text] [Related]
8. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
9. [Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma].
Cuenca R; Fernández-Cortijo J; Lima J; Fonollosa V; Simeón CP; Pico M; Soriano B; Vilardell M
Med Clin (Barc); 1990 Dec; 95(20):761-3. PubMed ID: 2151867
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
Marasini B; Casari S; Bestetti A; Maioli C; Cugno M; Zeni S; Turri O; Guagnellini E; Biondi ML
J Rheumatol; 2000 Nov; 27(11):2621-3. PubMed ID: 11093443
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.
Mok MY; Cheung BM; Lo Y; Leung RY; Wong WS; Lau CS
J Rheumatol; 2007 Nov; 34(11):2224-9. PubMed ID: 17937467
[TBL] [Abstract][Full Text] [Related]
12. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
[TBL] [Abstract][Full Text] [Related]
13. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous chromosome damage (micronuclei) in systemic sclerosis and Raynaud's phenomenon.
Porciello G; Scarpato R; Ferri C; Storino F; Cagetti F; Morozzi G; Bellisai F; Migliore L; Marcolongo R; Galeazzi M
J Rheumatol; 2003 Jun; 30(6):1244-7. PubMed ID: 12784397
[TBL] [Abstract][Full Text] [Related]
15. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.
Herrick AL; Rieley F; Schofield D; Hollis S; Braganza JM; Jayson MI
J Rheumatol; 1994 Aug; 21(8):1477-83. PubMed ID: 7983650
[TBL] [Abstract][Full Text] [Related]
16. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
17. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study.
Pamuk GE; Vural O; Turgut B; Demir M; Umit H; Tezel A
Am J Hematol; 2006 Oct; 81(10):753-9. PubMed ID: 16941615
[TBL] [Abstract][Full Text] [Related]
18. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
19. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
20. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.
Kallenberg CG; Vellenga E; Wouda AA; The TH
J Rheumatol; 1982; 9(6):878-84. PubMed ID: 7161779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
